INVASIVE PROCEDURES IN PATIENTS WITH HAEMOPHILIA ON EMICIZUMAB PROPHYLAXIS: REAL-WORLD CLINICAL EXPERIENCE IN SLOVENIA

被引：0
|
作者：
Rener, K. [1 ]
Pompe, B. [2 ]
Doma, S. Anzej [1 ]
Kotnik, B. Faganel [3 ]
Kitanovski, L. [3 ]
Zupan, I. Preloznik [1 ]
机构：
[1] Univ Med Ctr Ljubljana, Haematol, Ljubljana, Slovenia
[2] Univ Med Ctr Ljubljana, Orthoped Surg, Ljubljana, Slovenia
[3] Univ Med Ctr Ljubljana, Div Paediat, Ljubljana, Slovenia
来源：
HAEMOPHILIA | 2022年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO082
引用
收藏
页码：66 / 66
页数：1
相关论文
共 50 条
  • [41] Real-world analysis of haemophilia patients in China: A single centre's experience
    Song, Xuewen
    Liu, Wei
    Xue, Feng
    Zhong, Jia
    Yang, Yifan
    Liu, Yi
    Xie, Jipan
    Wu, Eric
    Zhang, Lei
    Shi, Jun
    Yang, Renchi
    HAEMOPHILIA, 2020, 26 (04) : 584 - 590
  • [42] Real-world experience of tixagevimab/cilgavimab prophylaxis in Japanese patients with immunodeficiency
    Inoue, Kento
    Tomomasa, Dan
    Nakagama, Yu
    Takeuchi, Hiroaki
    Tanaka, Yukie
    Tanimoto, Kousuke
    Kamiya, Takahiro
    Isoda, Takeshi
    Takagi, Masatoshi
    Tanaka, Keisuke
    Yoshifuji, Kota
    Miwa, Yuki
    Ohnishi, Hidenori
    Okada, Satoshi
    Mori, Takehiko
    Yasuda, Shinsuke
    Kido, Yasutoshi
    Morio, Tomohiro
    Kanegane, Hirokazu
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2025, 31 (02)
  • [43] Real-World Use of Emicizumab in Patients with Hemophilia with and without Inhibitors
    McCary, Isabella
    Guelcher, Christine
    Kuhn, Jan
    Butler, Regina
    Massey, Gita
    Guerrera, Michael F.
    Ballester, Lance
    Raffini, Leslie J.
    BLOOD, 2019, 134
  • [44] Real-World Safety of Emicizumab: Interim Analysis of the European Haemophilia Safety Surveillance (EUHASS) Database
    Nissen, Francis
    Jiang, Yanrong
    Hiew, Hwai Jing
    Aizenas, Martynas
    Tobaruela, Guillermo
    Jew, Lyle
    BLOOD, 2022, 140
  • [45] Real-world analysis of patients with haemophilia A and haemophilia A carriers in the United States: Demographics, clinical characteristics and costs
    Batt, Katharine
    Xing, Shan
    Kuharic, Maja
    Bullano, Michael
    Caicedo, Jorge
    Chakladar, Sreya
    Markan, Riddhi
    Farahbakhshian, Sepehr
    HAEMOPHILIA, 2023, 29 (03) : 809 - 818
  • [46] Experience of prophylaxis with Emicizumab in Ivoirian boys with severe haemophilia A: Preliminary data
    Lambert, Catherine
    Meite, N'Dogomo
    Sanogo, Ibrahima
    Hermans, Cedric
    HAEMOPHILIA, 2022, 28 : 17 - 17
  • [47] EMICIZUMAB PROPHYLAXIS IN ADULT PATIENTS WITH SEVERE HAEMOPHLIA A INHIBITORS: EXPERIENCE FROM A GREEK HAEMOPHILIA CENTRE
    Kouraba, A.
    Zannou, A.
    Gotsi, S.
    Chanos, A.
    Pirpiri, T.
    Kelaidis, E.
    Katsarou, O.
    HAEMATOLOGICA, 2021, 106 (09) : 32 - 32
  • [48] Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience
    Tagliaferri, Annarita
    Matichecchia, Annalisa
    Rivolta, Gianna F.
    Riccardi, Federica
    Quintavalle, Gabriele
    Benegiamo, Anna
    Rossi, Rossana
    Coppola, Antonio
    BLOOD TRANSFUSION, 2020, 18 (05) : 374 - 385
  • [49] Clinical Outcomes of Noninhibitor Patients with Hemophilia a Switching from Prophylaxis with Factor VIII to Emicizumab: A Meta-Analysis of Real-World Evidence Studies
    Escobar, Miguel A.
    Fan, Qi Angela
    Mokdad, Ali G.
    Tarantino, Michael D.
    Burgess, Benjamin
    Hawe, Emma
    Fernandez, Maria
    Bullano, Michael
    BLOOD, 2023, 142
  • [50] Current real-world prophylaxis data in severe haemophilia patients younger than 21 years old
    Neme, Daniela
    Cocca, Andrea
    Del Rio, Lina
    HAEMOPHILIA, 2023, 29 : 11 - 11
12345